Imaging services provider U.S. Diagnostic of West Palm Beach, FL, last week reported that one-time charges totaling $15.1 million were the cause of an $11.9 million net loss in the company's second quarter (end-June). USDL's loss was attributable in part
Imaging services provider U.S. Diagnostic of West Palm Beach, FL, last week reported that one-time charges totaling $15.1 million were the cause of an $11.9 million net loss in the company's second quarter (end-June).
USDL's loss was attributable in part to a $4.9 million charge to settle class-action lawsuits filed earlier this year relating to revelations about one of the company's mergers and acquisitions consultants (SCAN 8/6/97). Another charge was $2.8 million spent in the quarter on a settlement with former CEO Jeffrey Goffman, who left the company in the wake of the revelations. USDL also took a $3.7 million charge for asset-impairment losses related to goodwill, and another $3.7 million in professional fees related to the shareholders' suits and investigations of the company by NASDAQ and the Securities and Exchange Commission.
The good news for USDL came on the revenue side, with the company reporting sales of $57.5 million for the second quarter, compared with $15.6 million in the same period a year ago. USDL executives said that the quarter was a difficult one, but that it represented the end of the company's recent woes. USDL shareholders seemed to agree: On the NASDAQ exchange Friday, USDL shares closed at $8.06 a share, up over 3%, while the rest of the market tanked.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.